RoundAngle Advisors LLC Invests $1.70 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

RoundAngle Advisors LLC bought a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 198,456 shares of the biopharmaceutical company's stock, valued at approximately $1,695,000. Ocular Therapeutix comprises approximately 1.6% of RoundAngle Advisors LLC's holdings, making the stock its 25th biggest holding. RoundAngle Advisors LLC owned 0.13% of Ocular Therapeutix as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 1,015 shares during the last quarter. Essex Investment Management Co. LLC grew its holdings in shares of Ocular Therapeutix by 0.3% in the third quarter. Essex Investment Management Co. LLC now owns 443,677 shares of the biopharmaceutical company's stock worth $3,860,000 after purchasing an additional 1,168 shares during the last quarter. Amalgamated Bank increased its stake in shares of Ocular Therapeutix by 37.9% in the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock worth $37,000 after buying an additional 1,481 shares during the period. HighVista Strategies LLC raised its holdings in Ocular Therapeutix by 5.1% during the 3rd quarter. HighVista Strategies LLC now owns 65,027 shares of the biopharmaceutical company's stock valued at $566,000 after buying an additional 3,168 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Ocular Therapeutix by 36.9% during the 2nd quarter. Victory Capital Management Inc. now owns 17,403 shares of the biopharmaceutical company's stock valued at $119,000 after buying an additional 4,695 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors.

Insider Transactions at Ocular Therapeutix

In related news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the sale, the insider now directly owns 269,059 shares of the company's stock, valued at approximately $2,424,221.59. This represents a 1.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 3.50% of the company's stock.

Ocular Therapeutix Stock Performance

Shares of OCUL stock traded down $0.04 on Monday, reaching $8.01. The stock had a trading volume of 519,711 shares, compared to its average volume of 683,871. The stock has a market cap of $1.26 billion, a P/E ratio of -6.07 and a beta of 1.23. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. Ocular Therapeutix, Inc. has a 1 year low of $3.76 and a 1 year high of $11.77. The company has a 50 day simple moving average of $9.00 and a 200 day simple moving average of $8.99.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on OCUL. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. Scotiabank initiated coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of "Moderate Buy" and an average target price of $16.71.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.